ESMO 2022 | CROWN: CNS AEs do not increase in 3-year follow-up

Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, gives an overview of 3-year follow-up data in the Phase III CROWN trial (NCT03052608), which compared the efficacy of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor, to crizotinib in patients with non-small cell lung cancer (NSCLC). The incidence of central nervous system (CNS) adverse effects (AEs), which include cognitive, mood, speech and psychotic effects, did not increase after 3 years post-treatment. A majority of cases did not require intervention in when the dose was reduced, efficacy was not impacted. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.